Global Oral Antidiabetic Drugs Market Size study, by Drug and Regional Forecasts 2020-2027
発行: Bizwit Research & Consulting LLP
世界の経口抗糖尿病薬市場は、2019年に約268億米ドルの規模に達し、さらに2020～2027年に10.3％以上の成長率で成長する、と予想されています。世界各国での糖尿病患者の増加や人口高齢化などが挙げられます。他方、大手製薬企業が新型コロナウイルス感染症 (Covid-19) ワクチンの開発に精力を傾けているため、経口抗糖尿病薬の開発が遅れる恐れもあります。
当レポートでは、世界の経口式の糖尿病治療薬の市場について分析し、市場の基本構造 (バリューチェーンなど) や主な促進・抑制要因、全体的な市場規模の動向見通し (今後8年間分)、薬剤別および地域別の詳細動向、主要企業のプロファイル・市場シェアといった情報を取りまとめてお届けいたします。
Global Oral Antidiabetic Drugs Market Size study, by Drug (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 Receptor Agonist, Sodium - glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides) and Regional Forecasts 2020-2027.
Global Oral Antidiabetic Drugs Market is valued at approximately USD 26.8 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2020-2027. Oral anti-diabetic drugs can be defined as a medication consumed orally which are recommended to heal diabetes mellitus (type 2). It treats diabetes mellitus by reducing the level of blood sugar level. These drugs often known as oral antihyperglycemic agents or oral hypoglycemic agents. Oral anti-diabetic drugs are also recommended as monotherapy, however in acute cases, and can be provided in blend with insulin. Rising incidences of diabetes across the globe, increasing aging population, and rapidly growing research and development efforts by pharmaceutical manufacturers to promote the demand for oral drugs are the few other factors driving the market growth during the forecast period. According to the International Diabetic Federation (IDF), the prevalence of diabetes among adults (20-79 years) was about 463 million adults in 2019, and this estimation is likely to grow almost 700 million by the year 2045. Similarly, as per the IDF Diabetes Atlas in 2019, the number of diabetic patients in Europe is expected to reach around 68 million by 2045, with total health expenditure for diabetes almost USD 214 billion. This, in turn, is expected to accelerate the usage of Oral Antidiabetic Drugs all over the world. Amidst the COVID-19 outbreak around the world, the pharma industry is more concerned about the development of the COVID-19 vaccine, thus, R&D efforts for oral antidiabetic drugs is substantially decline. Though, the demand for oral anti-diabetic drugs is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at a significant rate in the forthcoming years. However, the high cost of oral antidiabetic drugs is one of the major factors impeding the growth of the market over the forecast period of 2020-2027.
The regional analysis of the global Oral Antidiabetic Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising prevalence of diabetes, coupled with the introduction of new anti-diabetic drugs with improve efficacy in the region. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as growing diabetic population, coupled with improving healthcare infrastructure would create lucrative growth prospects for the demand of Oral Antidiabetic Drugs in the region.
Major market player included in this report are:
Takeda Pharmaceutical Company Ltd.
Eli Lilly and Company
Boehringer Ingelheim Group
Merck & Co., Inc.,
Novartis International AG
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Dopamine -D2 Receptor Agonist
Sodium - glucose Cotransport -2 (SGLT-2) inhibitor
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2017, 2018
Base year - 2019
Forecast period - 2020 to 2027
Target Audience of the Global Oral Antidiabetic Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers